Similar articles

• The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.

  Nakamura A, Grossman S, Song K, Xega K, Zhang Y, Cvet D, Berger A, Shapiro G, Huszar D. Nakamura A, et al. Blood. 2022 May 5;139(18):2770-2781. doi: 10.1182/blood.2021014267. Blood. 2022. PMID: 35226739 Free PMC article.
• Activation of natural killer cells by rituximab in granulomatosis with polyangiitis.

  Urlaub D, Zhao S, Blank N, Bergner R, Claus M, Tretter T, Lorenz HM, Watzl C, Merkt W. Urlaub D, et al. Arthritis Res Ther. 2019 Dec 11;21(1):277. doi: 10.1186/s13075-019-2054-0. Arthritis Res Ther. 2019. PMID: 31829278 Free PMC article.
• The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.

  Le Garff-Tavernier M, Herbi L, de Romeuf C, Azar N, Roos-Weil D, Bonnemye P, Urbain R, Leblond V, Merle-Beral H, Vieillard V. Le Garff-Tavernier M, et al. Haematologica. 2015 Apr;100(4):e147-51. doi: 10.3324/haematol.2014.118083. Epub 2014 Dec 31. Haematologica. 2015. PMID: 25552707 Free PMC article. No abstract available.
• SUMO wrestling with Ras.

  Zhang H, Luo J. Zhang H, et al. Small GTPases. 2016 Apr 2;7(2):39-46. doi: 10.1080/21541248.2016.1161698. Epub 2016 Apr 8. Small GTPases. 2016. PMID: 27057691 Free PMC article. Review.
• [RITUXIMAB FOR THE TREATMENT OF PEMPHIGUS - A REVIEW OF RECENT STUDIES AND PERSONAL EXPERIENCE FROM THE RABIN MEDICAL CENTER AND THE SHEBA MEDICAL CENTER].

  Mimouni D, Baum S. Mimouni D, et al. Harefuah. 2020 Jan;159(1):31-33. Harefuah. 2020. PMID: 31930805 Review. Hebrew.